share_log

BridgeBio Pharma Analyst Ratings

Benzinga Analyst Ratings ·  Jan 23, 2023 06:37
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
01/23/2023 125.39% SVB Leerink $23 → $19 Maintains Outperform
11/18/2022 125.39% JP Morgan $20 → $19 Maintains Overweight
08/24/2022 172.84% Mizuho $25 → $23 Maintains Buy
07/26/2022 255.87% SVB Leerink $27 → $30 Maintains Outperform
05/24/2022 125.39% Goldman Sachs $24 → $19 Maintains Buy
05/06/2022 220.28% SVB Leerink $26 → $27 Maintains Outperform
03/16/2022 160.97% HC Wainwright & Co. $24 → $22 Maintains Buy
03/11/2022 113.52% JP Morgan $21 → $18 Maintains Overweight
03/09/2022 208.42% SVB Leerink $25 → $26 Maintains Outperform
03/04/2022 196.56% SVB Leerink $24 → $25 Maintains Outperform
12/28/2021 184.7% HC Wainwright & Co. $88 → $24 Maintains Buy
12/28/2021 184.7% SVB Leerink $66 → $24 Maintains Outperform
11/19/2021 682.92% SVB Leerink $68 → $66 Maintains Outperform
10/25/2021 943.89% HC Wainwright & Co. $87 → $88 Maintains Buy
10/04/2021 706.64% SVB Leerink $66 → $68 Maintains Outperform
09/10/2021 789.68% B of A Securities → $75 Upgrades Neutral → Buy
08/06/2021 682.92% SVB Leerink $71 → $66 Maintains Outperform
05/21/2021 848.99% UBS → $80 Initiates Coverage On → Buy
05/07/2021 848.99% Goldman Sachs $92 → $80 Maintains Buy
03/23/2021 789.68% SVB Leerink $67 → $75 Maintains Outperform
03/04/2021 920.17% Mizuho $56 → $86 Maintains Buy
02/09/2021 884.58% Goldman Sachs → $83 Reinstates → Buy
01/11/2021 932.03% HC Wainwright & Co. $64 → $87 Maintains Buy
12/10/2020 659.19% HC Wainwright & Co. $53 → $64 Maintains Buy
12/04/2020 421.95% SVB Leerink $39 → $44 Maintains Outperform
10/12/2020 528.71% HC Wainwright & Co. $50 → $53 Maintains Buy
06/25/2020 350.77% B of A Securities → $38 Initiates Coverage On → Neutral
05/19/2020 481.26% BTIG → $49 Initiates Coverage On → Buy
05/14/2020 362.63% SVB Leerink $41 → $39 Reiterates → Outperform
04/13/2020 493.12% HC Wainwright & Co. → $50 Initiates Coverage On → Buy
03/03/2020 410.08% JP Morgan $38 → $43 Maintains Overweight
02/19/2020 504.98% Mizuho → $51 Initiates Coverage On → Buy
07/26/2019 327.05% Raymond James → $36 Initiates Coverage On → Outperform
07/22/2019 350.77% JP Morgan → $38 Initiates Coverage On → Overweight
07/22/2019 350.77% Jefferies → $38 Initiates Coverage On → Buy
07/22/2019 303.32% SVB Leerink → $34 Initiates Coverage On → Outperform
07/22/2019 398.22% Goldman Sachs → $42 Initiates Coverage On → Buy
07/22/2019 493.12% Piper Sandler → $50 Initiates Coverage On → Overweight
07/22/2019 481.26% BMO Capital → $49 Initiates Coverage On → Outperform

What is the target price for BridgeBio Pharma (BBIO)?

The latest price target for BridgeBio Pharma (NASDAQ: BBIO) was reported by SVB Leerink on January 23, 2023. The analyst firm set a price target for $19.00 expecting BBIO to rise to within 12 months (a possible 125.39% upside). 10 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for BridgeBio Pharma (BBIO)?

The latest analyst rating for BridgeBio Pharma (NASDAQ: BBIO) was provided by SVB Leerink, and BridgeBio Pharma maintained their outperform rating.

When is the next analyst rating going to be posted or updated for BridgeBio Pharma (BBIO)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BridgeBio Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BridgeBio Pharma was filed on January 23, 2023 so you should expect the next rating to be made available sometime around January 23, 2024.

Is the Analyst Rating BridgeBio Pharma (BBIO) correct?

While ratings are subjective and will change, the latest BridgeBio Pharma (BBIO) rating was a maintained with a price target of $23.00 to $19.00. The current price BridgeBio Pharma (BBIO) is trading at is $8.43, which is out of the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment